Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).


TSXV:VPT - Post by User

Comment by G1945Von Feb 03, 2023 2:29pm
54 Views
Post# 35265555

RE:RE:CEO.CA @Yoyo

RE:RE:CEO.CA @Yoyo
GrahamB wrote: We are told by a poster on another board that GA told them that NICE was a "clerical error"

Exactly how doesn an evidenced based process, by experts, including one consultant paid by VPT change this, based on a clerical  error?

I had predicted the NICE outcome, and stand by my overall conclusion

We will wait and see....

 

 

•"Experts advised that more evidence is needed before VMS+ can be routinely used in the NHS. Experts disagreed about where VMS+ would provide the most benefit in the care pathway. One expert felt that VMS+ would provide little additional value than existing technologies."

Source:NICE Experts Comments

 

 

Source:Abstracted from UK NICE MIB Ventripoint 


WHAT did the Uk NICE expert panel(included a VPT paid consultant say about VPT?

 

"Two experts stated that, as VMS+ can be used with standard 2D echocardiography equipment, it requires less retraining of staff than current available 3D systems. However, the experts noted that VMS+ is more time consuming than fully automated echocardiograph systems, as it requires healthcare professionals to manually plot points on anatomical landmarks of the heart. Two experts felt that VMS+ would cost slightly more than current standard care due to the additional time it could take to complete an echocardiogram." 

 

•"Experts advised that more evidence is needed before VMS+ can be routinely used in the NHS. Experts disagreed about where VMS+ would provide the most benefit in the care pathway. One expert felt that VMS+ would provide little additional value than existing technologies."

Source:NICE Experts Comments

 

 

Source:Abstracted from UK NICE MIB Ventripoint 



Graham,

I (and most I'm sure) rather follow Dr. George Adams and his track record rather than your continual biased rambling.

G1945V

<< Previous
Bullboard Posts
Next >>